New drug strategy aims to keep myeloma at bay after transplant
NCT ID NCT03346135
Summary
This study is testing if giving the drug daratumumab after a patient's own stem cell transplant helps control multiple myeloma for a longer time. It involves 31 patients who have had the transplant. The main goal is to see if this extra treatment can prevent the cancer from progressing for at least one year after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.